4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
By Dean Seal
Shares of 4D Molecular Therapeutics rose after federal regulators granted regenerative medicine advanced therapy designation to its treatment for wet age-related macular degeneration.
The stock was up 5.7% at $20.13 in midday trading. Shares are still down about 9% year-to-date.
The clinical-stage biotherapeutics company said Thursday that the Food and Drug Administration granted the so-called RMAT designation to 4D-150 for intravitreal treatment of wed AMD.
The designation is based on 4D-150's potential to address unmet medical needs, the company said.
Chief Executive David Kirn said this was the first RMAT designation for an investigational treatment for wet AMD.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 21, 2023 12:16 ET (17:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis